RESUMO
Leigh syndrome (LS) is a heterogeneous disorder, usually due to a defect in oxidative metabolism. Typically, signs and symptoms commence in infancy or childhood, although rare cases of adult onset have been described. Progressive deterioration is the norm. The authors describe a 22-year-old woman with partial cytochrome c oxidase deficiency who developed fulminant LS following an acute febrile illness and who subsequently showed dramatic clinical and neuroradiologic improvement.
Assuntos
Deficiência de Citocromo-c Oxidase/tratamento farmacológico , Doença de Leigh/tratamento farmacológico , Doença de Leigh/enzimologia , Adulto , Ácido Ascórbico/administração & dosagem , Encéfalo/patologia , Quimioterapia Combinada , Feminino , Humanos , Doença de Leigh/diagnóstico , Imageamento por Ressonância Magnética , Indução de Remissão , Riboflavina/administração & dosagem , Tiamina/administração & dosagem , Ubiquinona/administração & dosagemRESUMO
Aerobic training has been shown to increase work and oxidative capacity in patients with mitochondrial myopathies, but the mechanisms underlying improvement are not known. We evaluated physiological (cycle exercise, 31P-MRS), biochemical (enzyme levels), and genetic (proportion of mutant/wild-type genomes) responses to 14 weeks of bicycle exercise training in 10 patients with heteroplasmic mitochondrial DNA (mtDNA) mutations. Training increased peak work and oxidative capacities (20-30%), systemic arteriovenous O2 difference (20%), and 31P-MRS indices of metabolic recovery (35%), consistent with enhanced muscle oxidative phosphorylation. Mitochondrial volume in vastus lateralis biopsies increased significantly (50%) and increases in deficient respiratory chain enzymes were found in patients with Complex I (36%) and Complex IV (25%) defects, whereas decreases occurred in 2 patients with Complex III defects (approximately 20%). These results suggest that the cellular basis of improved oxygen utilization is related to training-induced mitochondrial proliferation likely resulting in increased levels of functional, wild-type mtDNA. However, genetic analysis indicated the proportion of wild-type mtDNA was unchanged (3/9) or fell (6/9), suggesting a trend toward preferential proliferation of mutant genomes. The long-term implications of training-induced increases in mutant relative to wild-type mtDNA, despite positive physiological and biochemical findings, need to be assessed before aerobic training can be proposed as a general treatment option.
Assuntos
Exercício Físico/fisiologia , Miopatias Mitocondriais/fisiopatologia , Adulto , Biópsia por Agulha , Feminino , Humanos , Espectroscopia de Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Miopatias Mitocondriais/genética , Miopatias Mitocondriais/metabolismo , Miopatias Mitocondriais/patologia , Músculos/metabolismo , Músculos/patologia , Fatores de TempoRESUMO
We have reinvestigated a young woman, originally reported by us in 1983, who presented with exercise intolerance and lactic acidosis associated with severe deficiency of complex III and who responded to therapy with menadione and ascorbate. Gradually, she developed symptoms of a mitochondrial encephalomyopathy. Immunocytochemistry of serial sections of muscle showed a mosaic of fibers that reacted poorly with antibodies to subunits of complex III but reacted normally with antibodies to subunits of complexes I, II, or IV, suggesting a mutation of mtDNA. These findings demonstrate the diagnostic value of immunocytochemistry in identifying specific respiratory-chain deficiencies and, potentially, distinguishing between nuclear- or mtDNA-encoded defects. Sequence analysis revealed a stop-codon mutation (G15242A) in the mtDNA-encoded cytochrome b gene, resulting in loss of the last 215 amino acids of cytochrome b. PCR-RFLP analysis indicated that the G15242A mutation was heteroplasmic and was present in a high percentage (87%) of affected tissue (skeletal muscle) and a low percentage (0.7%) of unaffected tissue (blood) but was not detected in controls. Analysis of microdissected muscle fibers showed a significant correlation between the immunoreactivity toward the Rieske protein of complex III and the percentage of mutant mtDNA: immunopositive fibers had a median value of 33% of the G15242A mutation, whereas immunonegative, ragged-red fibers had a median value of 89%, indicating that the stop-codon mutation was pathogenic in this patient. The G15242A mutation was also present in several other tissues, including hair roots, indicating that it must have arisen either very early in embryogenesis, before separation of the primary germ layers, or in the maternal germ line. The findings in this patient are contrasted with other recently described patients who have mutations in the cytochrome b gene.
Assuntos
Códon de Terminação/genética , Grupo dos Citocromos b/genética , Complexo III da Cadeia de Transporte de Elétrons/deficiência , Encefalomiopatias Mitocondriais/genética , Mutação/genética , Adolescente , Adulto , Sequência de Aminoácidos , Sequência de Bases , Criança , Clonagem Molecular , Grupo dos Citocromos b/química , Análise Mutacional de DNA , DNA Mitocondrial/genética , Complexo III da Cadeia de Transporte de Elétrons/genética , Feminino , Fibroblastos , Humanos , Imuno-Histoquímica , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Encefalomiopatias Mitocondriais/patologia , Dados de Sequência Molecular , Fibras Musculares Esqueléticas/metabolismo , Fibras Musculares Esqueléticas/patologia , Músculo Esquelético/metabolismo , Músculo Esquelético/patologia , Reação em Cadeia da Polimerase , Polimorfismo de Fragmento de RestriçãoRESUMO
A 15-base pair, in-frame, deletion (9480del15) in the mitochondrial DNA (mtDNA)-encoded cytochrome c oxidase subunit III (COX III) gene was identified previously in a patient with recurrent episodes of myoglobinuria and an isolated COX deficiency. Transmitochondrial cell lines harboring 0, 97, and 100% of the 9480del15 deletion were created by fusing human cells lacking mtDNA (rho(0) cells) with platelet and lymphocyte fractions isolated from the patient. The COX III gene mutation resulted in a severe respiratory chain defect in all mutant cell lines. Cells homoplasmic for the mutation had no detectable COX activity or respiratory ATP synthesis, and required uridine and pyruvate supplementation for growth, a phenotype similar to rho(0) cells. The cells with 97% mutated mtDNA exhibited severe reductions in both COX activity (6% of wild-type levels) and rates of ATP synthesis (9% of wild-type). The COX III polypeptide in the mutant cells, although translated at rates similar to wild-type, had reduced stability. There was no evidence for assembly of COX I, COX II, or COX III subunits in a multisubunit complex in cells homoplasmic for the mutation, thus indicating that there was no stable assembly of COX I with COX II in the absence of wild-type COX III. In contrast, the COX I and COX II subunits were assembled in cells with 97% mutated mtDNA.
Assuntos
DNA Mitocondrial/genética , Complexo IV da Cadeia de Transporte de Elétrons/genética , Complexo IV da Cadeia de Transporte de Elétrons/metabolismo , Humanos , Deleção de Sequência , Células Tumorais CultivadasRESUMO
Two clinical subtypes of gyrate atrophy (GA) have been defined based on in vivo or in vitro evidence of response to vitamin B6 (pyridoxine), which is the cofactor of the enzyme ornithine aminotransferase (OAT) shown to be defective in GA. We identified the E318K mutation in the OAT gene, heterozygously in three patients and homozygously in one patient, all of whom were vitamin B6-responsive by previous in vivo and in vitro studies. Dose-dependent effects of the E318K mutation were observed in the homo- and heterozygotes in the OAT activity, increase of OAT activity in the presence of pyridoxal phosphate, and apparent Km for pyridoxal phosphate. The highest residual level of OAT activity and mildness of clinical disease correlated directly with the dose of the mutant E318K allele present in the patient.
Assuntos
Atrofia Girata/genética , Piridoxina/administração & dosagem , Sequência de Aminoácidos , Substituição de Aminoácidos , Sequência de Bases , DNA/química , DNA/genética , Análise Mutacional de DNA , Saúde da Família , Feminino , Genótipo , Atrofia Girata/sangue , Atrofia Girata/tratamento farmacológico , Heterozigoto , Humanos , Masculino , Mutação , Ornitina/sangue , Ornitina/efeitos dos fármacos , Ornitina-Oxo-Ácido Transaminase/genética , Ornitina-Oxo-Ácido Transaminase/metabolismo , Fenótipo , Mutação Puntual , Piridoxina/uso terapêutico , Resultado do TratamentoRESUMO
A 6-yr-old boy presented with muscle weakness, lactic acidemia, and insulin-dependent diabetes mellitus (IDDM). Using PCR and restriction enzyme analysis, he was found to have the classical A3248G mitochondrial DNA (mtDNA) mutation frequently associated with mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS). The mutation was confirmed by sequencing muscle mtDNA. The mutation in mtDNA from muscle, lymphoblasts, and blood was clearly demonstrable by standard methods using ethidium bromide staining. His mother also had IDDM, but no A3243G mutation could be detected in her blood or transformed lymphoblasts using the same PCR technique. When PCR was carried out in the presence of [32P]deoxycytidine triphosphate, subsequent autoradiography detected the presence of the mutation at low levels in mtDNA from the mother's lymphoblasts and blood. Study of the mother's muscle showed a mitochondrial myopathy, despite the fact that she was asymptomatic. We emphasize that the increased sensitivity of radiolabeled PCR may be necessary to detect small percentages of heteroplasmic A3243G mtDNA mutation in blood from diabetic subjects. Otherwise the incidence of mtDNA mutations in both IDDM and non-insulin dependent diabetes may be underestimated.
Assuntos
Diabetes Mellitus Tipo 1/complicações , Síndrome MELAS/complicações , Síndrome MELAS/genética , Mutação , Reação em Cadeia da Polimerase/métodos , Adulto , Autorradiografia , Criança , DNA Mitocondrial/genética , Transporte de Elétrons , Etídio , Feminino , Corantes Fluorescentes , Humanos , Síndrome MELAS/metabolismo , Masculino , Microscopia Eletrônica , Mitocôndrias Musculares/metabolismo , Músculos/patologia , Radioisótopos de FósforoRESUMO
PURPOSE: To describe the clinical characteristics of a chorioretinal disease with a gyrate atrophy-like phenotype and normal plasma ornithine. METHODS: One family with three men who had progressive chorioretinal disease and three additional patients with simplex cases were examined clinically and with standard electroretinography, electrooculography, and dark adaptometry. RESULTS: In the family, a 70-year-old man and his two sons (39 and 41 years of age) were affected. On ophthalmoscopy, sharply demarcated peripheral patches of retinal pigment epithelium and choroidal atrophy were seen to progress to the posterior pole in the father's eye. In three unrelated men (62, 70, and 80 years of age), chorioretinal atrophy was present in the mid- and far periphery. Visual acuity was normal in the two youngest of all six patients; however, electroretinogram and electrooculogram waves were reduced. Advanced visual field defects and visual acuity loss occurred in the four older patients. Electroretinogram and electrooculogram were reduced, and the dark adaptation thresholds were elevated. In all patients, serum ornithine levels were normal. Ornithine-delta-aminotransferase activity in cultured skin fibroblasts and the apparent Michaelis constant (Km) for ornithine and alpha-ketoglutarate were within the normal range in all patients. CONCLUSIONS: A gyrate atrophy-like phenotype can result from causes other than deficient ornithine-delta-aminotransferase. Its occurrence in three male members in two generations in one family suggests an autosomal dominant inheritance in at least some such patients.
Assuntos
Atrofia Girata/genética , Ornitina/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Atrofia , Corioide/patologia , Corioide/fisiopatologia , Adaptação à Escuridão , Eletroculografia , Eletrorretinografia , Angiofluoresceinografia , Fundo de Olho , Atrofia Girata/sangue , Atrofia Girata/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Linhagem , Fenótipo , Retina/patologia , Retina/fisiopatologia , Acuidade Visual/fisiologia , Campos Visuais/fisiologiaRESUMO
We have identified a 15-bp microdeletion in a highly conserved region of the mitochondrially encoded gene for cytochrome c oxidase (COX) subunit III in a patient with severe isolated COX deficiency and recurrent myoglobinuria. The mutant mitochondrial DNA (mtDNA) comprised 92% of the mtDNA in muscle and 0.7% in leukocytes. Immunoblots and immunocytochemistry suggested a lack of assembly or instability of the complex. Microdissected muscle fibres revealed significantly higher portions of mutant mtDNA in COX-negative than in COX-positive fibres. This represents the first case of isolated COX deficiency to be defined at the molecular level.
Assuntos
Deficiência de Citocromo-c Oxidase , Complexo IV da Cadeia de Transporte de Elétrons/genética , Mioglobinúria/enzimologia , Mioglobinúria/genética , Deleção de Sequência , Adolescente , Sequência de Aminoácidos , Animais , Sequência de Bases , DNA/genética , DNA Mitocondrial/genética , Complexo IV da Cadeia de Transporte de Elétrons/química , Feminino , Genótipo , Histocitoquímica , Humanos , Dados de Sequência Molecular , Músculo Esquelético/enzimologia , Fenótipo , Conformação Proteica , Recidiva , Homologia de Sequência de AminoácidosRESUMO
Monoclonal antibodies recognizing the mitochondrially encoded subunits I and II, and the nuclear-encoded subunits IV, Va, Vb and VIc of human cytochrome-c oxidase were generated. These antibodies are highly specific and allow the assessment of subunit steady-state levels in crude cell extracts and tissue sections. In the experimental human cell line 143B206, which is devoid of mitochondrial DNA, immunovisualization with the antibodies revealed that the nuclear-encoded subunits IV and Va were present in amounts close to that of the parental cell line despite the absence of the mitochondrially encoded subunits. In contrast, the nuclear-encoded subunits Vb and VIc were severely reduced in cell line 143B206, suggesting that unassembled nuclear-encoded subunits are degraded at different rates. In skeletal muscle sections of a patient with chronic progressive external ophthalmoplegia known to harbor the 'common deletion' in a subpopulation of her mitochondrial DNA, most cytochrome-c oxidase activity negative fibers had greatly reduced levels of subunits I, II, Va, Vb and VIc of cytochrome-c oxidase. The steady-state level of subunit IV, however, was less affected. This was particularly evident in cytochrome-c oxidase activity negative fibers with accumulated mitochondria ('ragged-red' fibers) where immunodetection with anti-subunit IV resulted in intense staining. The data presented in this paper demonstrate that the battery of monoclonal antibodies can be employed for diagnostic purposes to analyze steady-state levels of mitochondrially and nuclear-encoded subunits of cytochrome-c oxidase.
Assuntos
Anticorpos Monoclonais/imunologia , Complexo IV da Cadeia de Transporte de Elétrons/química , Mitocôndrias Musculares/enzimologia , Oftalmoplegia Externa Progressiva Crônica/enzimologia , Animais , Western Blotting , Bovinos , Linhagem Celular , Núcleo Celular/metabolismo , DNA Mitocondrial/genética , Complexo IV da Cadeia de Transporte de Elétrons/análise , Complexo IV da Cadeia de Transporte de Elétrons/imunologia , Feminino , Humanos , Camundongos , Mitocôndrias Cardíacas/enzimologia , Músculo Esquelético/enzimologia , Oftalmoplegia Externa Progressiva Crônica/genética , Conformação Proteica , Deleção de SequênciaRESUMO
Hereditary tyrosinaemia type I, a severe autosomal recessive metabolic disease, affects the liver and kidneys and is caused by deficiency of fumarylacetoacetate hydrolase (FAH). Mice homozygous for a FAH gene disruption have a neonatal lethal phenotype caused by liver dysfunction and do not represent an adequate model of the human disease. Here we demonstrate that treatment of affected animals with 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3-cyclohexanedione abolished neonatal lethality, corrected liver function and partially normalized the altered expression pattern of hepatic mRNAs. The prolonged lifespan of affected animals resulted in a phenotype analogous to human tyrosinaemia type I including hepatocellular carcinoma. The adult FAH-/- mouse will serve as useful model for studies of the pathophysiology and treatment of hereditary tyrosinaemia type I as well as hepatic cancer.
Assuntos
Erros Inatos do Metabolismo dos Aminoácidos/tratamento farmacológico , Cicloexanonas/uso terapêutico , Inibidores Enzimáticos/uso terapêutico , Hepatopatias/tratamento farmacológico , Nitrobenzoatos/uso terapêutico , Tirosina/sangue , Erros Inatos do Metabolismo dos Aminoácidos/genética , Erros Inatos do Metabolismo dos Aminoácidos/patologia , Aminoácidos/sangue , Animais , Cicloexanonas/toxicidade , Modelos Animais de Doenças , Inibidores Enzimáticos/toxicidade , Feminino , Heptanoatos/metabolismo , Humanos , Hidrolases/deficiência , Fígado/efeitos dos fármacos , Fígado/ultraestrutura , Hepatopatias/genética , Hepatopatias/patologia , Neoplasias Hepáticas/induzido quimicamente , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Nitrobenzoatos/toxicidade , Pâncreas/patologia , RNA Mensageiro/metabolismo , alfa-Fetoproteínas/metabolismoRESUMO
A 45-month-old girl with 5-oxoprolinuria (pyroglutamic aciduria), hemolysis, and marked glutathione depletion caused by deficiency of glutathione synthetase was followed before and during treatment with ascorbate or N-acetylcysteine. High doses of ascorbate (0.7 mmol/kg per day) or N-acetylcysteine (6 mmol/kg per day) were given for 1 to 2 weeks without any obvious deleterious side effects. Ascorbate markedly increased lymphocyte (4-fold) and plasma (8-fold) levels of glutathione. N-Acetylcysteine also increased lymphocyte (3.5-fold) and plasma (6-fold) levels of glutathione. After these treatments were discontinued, lymphocyte and plasma glutathione levels decreased rapidly to pretreatment levels. Ascorbate treatment was extended for 1 year, and lymphocyte (4-fold) and plasma (2- to 5-fold) glutathione levels remained elevated above baseline. In parallel, the hematocrit increased from 25.4% to 32.6%, and the reticulocyte count decreased from 11% to 4%. The results demonstrate that ascorbate and N-acetylcysteine can decrease erythrocyte turnover in patients with hereditary glutathione deficiency by increasing glutathione levels.
Assuntos
Acetilcisteína/uso terapêutico , Ácido Ascórbico/uso terapêutico , Glutationa Sintase/deficiência , Pré-Escolar , Feminino , Glutationa Sintase/análise , Glutationa Sintase/sangue , Humanos , Linfócitos/enzimologia , Erros Inatos do Metabolismo/sangue , Erros Inatos do Metabolismo/tratamento farmacológico , Vitamina E/uso terapêuticoAssuntos
Erros Inatos do Metabolismo dos Aminoácidos/complicações , Cardiomiopatia Dilatada/etiologia , Oxo-Ácido-Liases/deficiência , Erros Inatos do Metabolismo dos Aminoácidos/patologia , Cardiomiopatia Dilatada/enzimologia , Cardiomiopatia Dilatada/patologia , Evolução Fatal , Cromatografia Gasosa-Espectrometria de Massas , Ventrículos do Coração/patologia , Humanos , Lactente , MasculinoRESUMO
Recently, we described a patient with severe exercise intolerance and episodic myoglobinuria, associated with marked impairment of succinate oxidation and deficient activity of succinate dehydrogenase and aconitase in muscle mitochondria (1). We now report additional enzymatic and immunological characterization of mitochondria. In addition to severe deficiency of complex II, manifested by reduction of succinate dehydrogenase and succinate:coenzyme Q oxidoreductase activities to 12 and 22% of normal, respectively, complex III activity was reduced to 37% and rhodanese to 48% of normal. Furthermore, although complex I activity was not measured, immunoblot analysis of complex I showed deficiency of the 39-, 24-, 13-, and 9-kD peptides with lesser reductions of the 51- and 18-kD peptides. Immunoblots of complex III showed markedly reduced levels of the mature Rieske protein in mitochondria and elevated levels of its precursor in the cytosol, suggesting deficient uptake into mitochondria. Immunoreactive aconitase was also low. These data, together with the previous documentation of low amounts of the 30-kD iron-sulfur protein and the 13.5-kD subunit of complex II, compared to near normal levels of the 70-kD protein suggest a more generalized abnormality of the synthesis, import, processing, or assembly of a group of proteins containing iron-sulfur clusters.
Assuntos
Aconitato Hidratase/deficiência , Proteínas Ferro-Enxofre/metabolismo , Mitocôndrias Musculares/enzimologia , Miopatias Mitocondriais/enzimologia , Complexos Multienzimáticos/metabolismo , NAD(P)H Desidrogenase (Quinona)/metabolismo , Oxirredutases/metabolismo , Succinato Desidrogenase/deficiência , Succinato Desidrogenase/metabolismo , Adulto , Citrato (si)-Sintase/metabolismo , Complexo II de Transporte de Elétrons , Complexo III da Cadeia de Transporte de Elétrons/metabolismo , Humanos , Proteínas Ferro-Enxofre/análise , Masculino , Modelos Biológicos , Tiossulfato Sulfurtransferase/metabolismoRESUMO
Mice homozygous for the c14CoS albino deletion die as neonates as a result of liver dysfunction. Previous mapping studies have associated this defect with a 310-kb fragment encoding the hepatocyte-specific developmental regulation locus (alf/hsdr-1). The gene encoding fumarylacetoacetate hydrolase (Fah), a metabolic enzyme that catalyzes the last step of tyrosine catabolism, also maps to the same deletion interval. To test whether the neonatal defects found in the albino deletion mutants are attributable to loss of Fah, and not to another gene mapping to the deletion, we have generated Fah mutant mice by gene targeting in embryonic stem cells. Fah-deficient mice die within 12 hr after birth from hypoglycemia and liver dysfunction. In addition, the same pattern of altered liver mRNA expression found in the albino deletion mutants was also found in affected animals. We conclude that the neonatal lethal and liver dysfunction phenotype of the alf/hsdr-1 deletion is entirely attributable to loss of Fah.
Assuntos
Albinismo/genética , Hidrolases/genética , Hepatopatias/genética , Albinismo/sangue , Albinismo/mortalidade , Albinismo/patologia , Animais , Animais Recém-Nascidos/genética , Animais Recém-Nascidos/fisiologia , Sequência de Bases , Células Cultivadas , Retículo Endoplasmático/ultraestrutura , Deleção de Genes , Expressão Gênica/fisiologia , Hidrolases/deficiência , Hidrolases/fisiologia , Hepatopatias/sangue , Hepatopatias/patologia , Camundongos , Microscopia Eletrônica , Dados de Sequência Molecular , Fenótipo , RNA Mensageiro/genética , Tirosina/metabolismoRESUMO
Monoclonal and polyclonal antibodies specific to the two isoforms of subunit VIa of bovine cytochrome c oxidase were generated and used to study the tissue distribution of this subunit pair in beef, human and rat. The so-called H-(heart) form was found exclusively in heart and skeletal muscle, whereas the so-called L-(liver) form was the only isoform present in brain, kidney, liver and smooth muscle. Little or no L-form was detected in skeletal muscle. In bovine heart no subunit VIa-L was detected, while in human heart the subunit VIa-H and VIa-L isoforms were present in roughly equal proportions. These results imply that, in humans, the deficiency of a subunit VIa isoform may have a different effect on the physiology of heart then on the physiology of skeletal muscle.
Assuntos
Complexo IV da Cadeia de Transporte de Elétrons/análise , Isoenzimas/análise , Músculo Liso/enzimologia , Músculos/enzimologia , Sequência de Aminoácidos , Animais , Anticorpos , Anticorpos Monoclonais , Encéfalo/enzimologia , Bovinos , Complexo IV da Cadeia de Transporte de Elétrons/química , Humanos , Immunoblotting , Fígado/enzimologia , Dados de Sequência Molecular , Miocárdio/enzimologia , RatosRESUMO
In a 4.5-month-old boy presenting with marked muscular hypotonia in the neonatal period, hepatomegaly, cardiac hypertrophy, recurrent hypoglycemia, metabolic acidosis, and secondary carnitine deficiency, there was a considerable urinary excretion of 3-methylglutaconic and 3-methylglutaric acid. Estimation of 3-methylglutaconyl-CoA hydratase, 3-hydroxy-3-methylglutaryl-CoA lyase and initial enzymatic steps of cholesterol biosynthesis in cultured fibroblasts and in different tissues postmortem revealed no enzyme deficiency. Analyses of the respiratory chain in postmortem tissues demonstrated severe impairment of complex I (NADH ubiquinone oxidoreductase) and complex IV (cytochrome c oxidase) activities in skeletal muscle and reduced complex IV activity in heart.
Assuntos
Acidose Láctica/complicações , Cardiomiopatia Hipertrófica/complicações , Glutaratos/urina , Erros Inatos do Metabolismo/complicações , Miopatias Mitocondriais/enzimologia , Transtornos Respiratórios/complicações , Acidose Láctica/metabolismo , Cardiomiopatia Hipertrófica/metabolismo , Cardiomiopatia Hipertrófica/patologia , Complexo IV da Cadeia de Transporte de Elétrons/metabolismo , Humanos , Hidroliases/metabolismo , Lactente , Leucina/metabolismo , Masculino , Meglutol/análogos & derivados , Meglutol/urina , Erros Inatos do Metabolismo/metabolismo , Erros Inatos do Metabolismo/patologia , Miopatias Mitocondriais/patologia , Transtornos Respiratórios/metabolismo , Transtornos Respiratórios/patologiaRESUMO
We report a patient with mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes treated with riboflavin and nicotinamide for 18 months, during which time previously frequent encephalopathic spells ceased. To confirm clinical benefit, we withdrew treatment and monitored response with muscle 31P magnetic resonance spectroscopy (MRS) and sural nerve conduction studies. Of three prospectively chosen MRS variables, two changed coincidentally with clinical end points; phosphocreatine (PCr)/adenosine triphosphate recovery rates fell in parallel with sural nerve sensory amplitudes, and a drop in muscle bioenergetic efficiency (relationship of inorganic phosphate/PCr to the accelerating force of contracting muscle) coincided with development of encephalopathy. Investigations revealed a deficiency of respiratory complex I and mutation of the mitochondrial tRNA(Leu)(UUR). We suggest that a defective cellular energy state in mitochondrial disease may be partially treatable and that changes seen in appropriate muscle spectroscopy studies may parallel improvement in brain and peripheral nerve function.
Assuntos
Síndrome MELAS/genética , Mitocôndrias Musculares/química , Mutação , RNA de Transferência de Leucina/genética , Adulto , Quimioterapia Combinada , Feminino , Humanos , Síndrome MELAS/tratamento farmacológico , Síndrome MELAS/fisiopatologia , Espectroscopia de Ressonância Magnética , Músculos/efeitos dos fármacos , Músculos/metabolismo , Condução Nervosa/fisiologia , Niacinamida/uso terapêutico , Fosfatos/metabolismo , Riboflavina/uso terapêuticoRESUMO
Gyrate atrophy (GA) is an autosomal recessive eye disease involving a progressive loss of vision due to chorioretinal degeneration in which the mitochondrial matrix enzyme ornithine aminotransferase (OAT) is defective. Two sisters with GA are described in this study in whom an A-to-G substitution at the 3' splice acceptor site of intron 4 in one allele of the OAT gene results in a truncated OAT mRNA devoid of exon 5 sequence. The mutation in the other allele was identified to be a mis-sense mutation at codon 318 by denaturing gradient gel electrophoresis and direct sequencing of the polymerase chain reaction (PCR)-amplified DNA. Thus, these GA patients are compound heterozygotes with respect to mutations in the OAT gene that result in inactivation of OAT.
Assuntos
Atrofia Girata/genética , Ornitina-Oxo-Ácido Transaminase/genética , Splicing de RNA , Adenina , Sequência de Bases , DNA , Feminino , Guanina , Humanos , Dados de Sequência Molecular , Mutação , Reação em Cadeia da PolimeraseRESUMO
A generalized deficiency of the mitochondrial matrix enzyme ornithine aminotransferase (OAT) is the inborn error in gyrate atrophy (GA), an autosomal recessive degenerative disease of the retina and choroid of the eye. Mutations in the OAT gene show a high degree of molecular heterogeneity in GA, reflecting the genetic heterogeneity in this disease. Using the combined techniques of PCR, denaturing gradient gel electrophoresis, and direct sequencing, we have identified three nonsense-codon mutations and one nonsense codon-generating mutation of the OAT gene in GA pedigrees. Three of them are single-base substitutions, and one is a 2-bp deletion resulting in a reading frameshift. A nonsense codon created at position 79 (TGA) by a frameshift and nonsense mutations at codons 209 (TAT----TAA) and 299 (TAC----TAG) result in abnormally low levels of OAT mRNA in the patient's skin fibroblasts. A nonsense mutation at codon 426 (CGA----TGA) in the last exon, however, has little effect on the mRNA level. Thus, the mRNA level can be reduced by nonsense-codon mutations, but the position of the mutation may be important, with earlier premature-translation termination having a greater effect than a later mutation.
Assuntos
Atrofia Girata/genética , Ornitina-Oxo-Ácido Transaminase/genética , Adulto , Sequência de Aminoácidos , Sequência de Bases , Códon , Eletroforese em Gel de Poliacrilamida , Humanos , Masculino , Dados de Sequência Molecular , Mutação , Desnaturação de Ácido Nucleico , Reação em Cadeia da Polimerase , RNA Mensageiro/biossínteseRESUMO
Gyrate atrophy (GA) is an autosomal recessive chorioretinal degenerative disease of the eye caused by an inborn defect of the nuclear encoded mitochondrial enzyme ornithine aminotransferase (OAT). We have described previously a GA patient with a 5.0-kilobase pair truncated EcoRI OAT gene fragment and the absence of OAT mRNA on Northern blot analysis. Cloning and sequencing analysis of the truncated gene fragment revealed a 1,072-base pair (bp) deletion including the entire exon 6, starting in intron 5, 172 bp upstream of exon 6 and ending in intron 6, 772 bp downstream of exon 6. A short direct repeat sequence (AGGAGC), resembling the sequence shown to cause DNA polymerase alpha to pause, and sequences capable of forming hairpin loops were both present at the 5' and 3' break-points of the deletion. Reverse transcription-polymerase chain reaction amplification of the patient's RNA with OAT primers yielded DNA fragments of two different sizes, consistent with a low level expression of OAT mRNA. Direct sequencing of the smaller fragment demonstrated the complete absence of exon 6 sequence in the mRNA predicted from the deletion, causing a reading frame shift which results in a premature termination codon at position 192. The mutation in the other allele has been demonstrated by polymerase chain reaction, denaturing gradient gel electrophoresis, and direct sequencing also to be a premature termination codon in exon 6. The absence of detectable OAT mRNA in this patient is consistent with these premature termination mutations because they have been shown to decrease the level of mRNA, especially if present early in the coding sequence.